Jul 15, 2019
Carbiotix, an award winning pre-clinical stage therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases, has been selected as one of the top 15 most promising biotech startups in Europe by Startup City.
"Being selected as one of the 15 most promising startups in Europe is an honor and I believe reflects our overall competitive position and potential to develop effective microbiome therapeutics across multiple disease areas. We are entering an exciting phase of company’s development, where our work over the past four years with our prebiotic fiber AXOS, low cost gut health testing platform and early therapeutics development, will be used as a base to accelerate the clinical introduction of two therapeutic products and hopefully many more over the coming years," says Carbiotix CEO, Kristofer Cook.
Startup City is a US based independent platform for decision makers in various industries, providing an inside look at various solutions from the burgeoning startup ecosystem. Startup City operates the Startup City Magazine and website that aim to bring together investors, accelerators, CIOs, and CEOs with startups under one roof to shed light on audacious solutions. This is the first year that Startup City has selected and published a list of the top 15 promising biotech startups based exclusively in Europe.Go Back